Immunization with the long-acting monoclonal antibody nirsevimab may provide stronger protection against hospitalizations for ...

The monoclonal antibody nirsevimab (Beyfortus) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection, the randomized, pragmatic ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving them. Factors such as older maternal age, private insurance, and receipt of ...

Maternal RSV vaccination and infant nirsevimab immunization were safe and effective when administered alone or sequentially.

The monoclonal antibody nirsevimab (Beyfortus) protected young infants against hospitalization for respiratory syncytial virus (RSV), pediatric intensive care unit (PICU) admissions, and mechanical ...

Six recent studies conclude that maternal respiratory syncytial virus (RSV) vaccination and the long-acting monoclonal ...

Please provide your email address to receive an email when new articles are posted on . Nirsevimab may offer protection for a period longer than a typical 5-month RSV season. Further investigation is ...

A single injection of the experimental agent nirsevimab ahead of respiratory syncytial virus (RSV) season protects healthy infants from lower respiratory tract infections associated with the pathogen, ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden of ...

Please provide your email address to receive an email when new articles are posted on . The findings support CDC’s current recommendations for administration of nirsevimab. Nirsevimab is currently ...

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc AZN and Sanofi SA's SNY nirsevimab has a favorable benefit-risk profile to prevent respiratory ...

During the first respiratory syncytial virus (RSV) season in France, passive infant immunisation with nirsevimab was associated with a lower risk for hospitalisation for RSV-related lower respiratory ...